⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8105465 | 0.88 | PARP1 (0.35) | — | |
| SCHEMBL8090361 | 0.83 | CYP3A4 (0.32) | — | |
| SCHEMBL8095474 | 0.82 | F2 (0.32) | — | |
| Water SCHEMBL8097685 | 0.81 | F2 (0.31) | — | |
| SCHEMBL8096885 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL8099224 | 0.79 | KDM4E (0.35) | — | |
| SCHEMBL8107056 | 0.78 | — | — | |
| SCHEMBL8096496 | 0.77 | — | — | |
| SCHEMBL8096882 | 0.77 | HPGD (0.34) | — | |
| SCHEMBL8099673 | 0.76 | GABRA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0626372-B1 | 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]benzenecarboximid-amides for the treatment of glaucoma | UCB SA (BE) | 2000-12-20 | — | — | EP | claimed |
| US-5385927-A | Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides and their use in treating glaucoma | U C B, S.A. (BE) | 1995-01-31 | — | — | US | claimed |
| EP-0626372-A1 | 2-hydroxy-3- 1-(1H-imidazol-4-yl)alkyl benzenecarboximid-amides for the treatment of glaucoma | U C B, S.A. (BE) | 1994-11-30 | — | — | EP | claimed |
| EP-0626372-B1 | 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]benzenecarboximid-amides for the treatment of glaucoma | UCB SA (BE) | 2000-12-20 | — | — | EP | disclosed |
| EP-0626372-B1 | 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]benzenecarboximid-amides for the treatment of glaucoma | UCB SA (BE) | 2000-12-20 | — | — | EP | disclosed |
| US-5385927-A | Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides and their use in treating glaucoma | U C B, S.A. (BE) | 1995-01-31 | — | — | US | disclosed |
| US-5385927-A | Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides and their use in treating glaucoma | U C B, S.A. (BE) | 1995-01-31 | — | — | US | disclosed |
| US-5385927-A | Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides and their use in treating glaucoma | U C B, S.A. (BE) | 1995-01-31 | — | — | US | disclosed |
| EP-0626372-A1 | 2-hydroxy-3- 1-(1H-imidazol-4-yl)alkyl benzenecarboximid-amides for the treatment of glaucoma | U C B, S.A. (BE) | 1994-11-30 | — | — | EP | disclosed |
| EP-0626372-A1 | 2-hydroxy-3- 1-(1H-imidazol-4-yl)alkyl benzenecarboximid-amides for the treatment of glaucoma | U C B, S.A. (BE) | 1994-11-30 | — | — | EP | disclosed |
| EP-0626372-A1 | 2-hydroxy-3- 1-(1H-imidazol-4-yl)alkyl benzenecarboximid-amides for the treatment of glaucoma | U C B, S.A. (BE) | 1994-11-30 | — | — | EP | disclosed |